Position of the Transparency Council – Lynparza (olaparib)
At its meeting on 9 June 2025, the Transparency Council adopted position No. 68/2025 on the appraisal of drug Lynparza (olaparib) under drug program B.148. “Treatment of patients with endometrial cancer (ICD-10: C54)”